Classifications

• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
  • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
  • A23L33/12—Fatty acids or derivatives thereof
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

• This invention relates to blends or mixtures of polyunsaturated fatty acid-containing microbial oils and to uses thereof.
• this invention concerns the use of such oils as an additive or supplement for human diets, for example, as an additive to infant formula.
• PUFAs long chain polyunsaturated fatty acids
• PUFAs polyunsaturated fatty acids
• Certain of these long chain acids, such as arachidonic acid (ARA) cannot be synthesized de novo in humans. Only by metabolizing linoleic acid (LOA), which is converted to gamma linolenic acid
• GLA eicosapentaenoic acid
• DHA docosahexaneoic acid
• Infancy is the most significant period of rapid growth in a human's life.
• An infant can increase its body weight by three times or more during its first year of life. Accordingly, it is critical that the infant receive adequate amounts of PUFAs to insure proper structural and organ development.
• Human breast milk contains high levels of PUFAs in which the ratio of ARA to EPA is typically about 20:1. However, many women choose not to breast feed their infants for either part or all of the first year of the infant's life.
• Clandinin et al. disclose an infant formula prepared from a blend of vegetable oil and egg yolk lipid and/or fish oil which can provide a total fat composition comparable to that of human breast milk.
• a preferable composition comprises from 75 to 95 parts by weight egg yolk and 5 to 25 parts vegetable oil. This composition is the entire lipid content of the infant formula and it is not economical to prepare.
• the infant formula disclosed by Clandinin et al. results in an EPA level which is 16 times higher than the level of EPA in human breast milk and an ARA level which is only one quarter that of breast milk.
• DE 3603000A1 discloses a computer profile of a highly polyunsaturated acid fat mixture and discusses the use of such a mixture to produce infant formulas.
• Sources of the fatty acids are listed as certain types of macroalgae (i.e. seaweed), fish oil, organ fats from beef and pork, and highly refined egg yolk oil.
• macroalgae i.e. seaweed
• fish oil i.e. fish oil
• organ fats from beef and pork and highly refined egg yolk oil.
• a potential source of DHA and ARA is said to be macroalgae, but only of the seaweed types. There is no suggestion to use microbes of any type, much less microbial oil.
• PUFA-enriched additive the composition of which when added to commercial infant formula will provide desired long chain PUFAs in amounts comparable to the amounts of those PUFAs found in human breast milk.
• This invention relates to the use of microbial oils which contain long chain polyunsaturated fatty acids. Additionally, in various embodiments, fish oil and/or vegetable oils can be blended with such microbial oils to form desired compositions.
• the compositions can be used as dietary supplements, particularly as additives for infant formula, as well as for pharmaceutical and cosmetic applications.
• the invention also relates to economically viable processes for altering the long chain polyunsaturated fatty acid composition of infant formula and/or baby food.
• the altered composition resembles that of human breast milk.
• the present invention concerns blends, or mixtures, containing unmodified microbial oils.
• unmodified means not chemically or covalently altered.
• references to “microbial oil” or “oil” mean, unless otherwise specifically stated, unmodified oil.
• “Microbial oils” or “single cell oils” are those oils naturally produced by microorganisms during their lifespan. Such oils can be high in long chain PUFAs. The applicant has discovered that certain of these oils, when blended with other microbial oils, fish oils, vegetable oils, or any combination thereof, can produce a composition useful for dietary, pharmaceutical or cosmetic purposes.
• microbial oils for example, can be obtained by, for example, the processes disclosed in above-referenced U.S. Patent Applications 07/496,572, 07/479,135, EP322,227 (Ya ada et al., Suntory) or U.S. Patent Application 07/645,454.
• the disclosure of each of these references is specifically incorporated by reference herein.
• the present invention encompasses the use of a single-microbial oil containing at least two desirable PUFAs, such as ARA and DHA.
• the most preferred microbial oils are those rich in an omega-3 or omega-6 PUFA, especially DHA, GLA or ARA. These PUFAs typically are missing from, or are inadequately provided in, dietary supplements such as infant formulas or baby food.
• "Infant formula” as used herein means an enteral nutritional product which can be substituted for human breast milk in feeding infants and typically is composed of a desired percentage of fat mixed with desired percentages of carbohydrates and proteins in an aqueous solution. Frequently micronutrients, such as trace metals and vitamins or other desired additives are present. Examples of such micronutrients and other additives are disclosed by Clandinin et al., U.S. Patent No. 4,670,285, the disclosure of which is incorporated herein by reference.
• types of oils from different microbes can be mixed together to obtain a desired composition.
• PUFA-containing microbial oil can be blended with fish oil, vegetable oil or a mixture of both tc obtain a desired composition.
• An objective in mixing the oils is to obtain an additive which will provide an infant formula with a desired omega-3 and omega-6 PUFA composition similar tc that found in breast milk. While the proportion of the desired fatty acids in a microbial oil can vary, this proportion can easily be determined and the amount of oil adjusted to provide the desired amount of PUFA. Similarly, the percentage of desired PUFA in fish oil or vegetable oils can easily be determined and the amount of the oil to be added can be adjusted as necessary to achieve the desired results.
• “Fish oils” are those oils obtained from fish. Such oils typically contain DHA in amounts ranging from 3% to about 20%. Typically, however, fish oils also contain EPA which depresses the production of ARA in the body. The addition of a microbial oil containing high levels of ARA to fish oil-containing compositions substantially overcomes that problem.
• “Vegetable oil” includes all those oils from plants which contain long chain PUFAs. Typically, vegetable oils do not contain long chain PUFAs (PUFAs at least 20 carbons long), which is why animal organ oils are usually characterized as the source of PUFAs. Thus, vegetarians, especially vegetarian mothers, can have a diet containing inadequate amounts of PUFAs.
• Vegetable oils known to contain PUFAs may contain GLA.
• GLA is a C18:3 omega-6 PUFA.
• Such oils include black currant seed oil, borage oil and primrose oil, While GLA is the metabolic precursor to ARA, the process of conversion is very slow, requiring the participation of the enzyme ⁇ 6-desaturase. This enzyme is present in humans in very low levels. Burre, et al. , Lipids, 25:354-356 (1990). Thus, it would be preferable to provide the body with ARA rather than its precursor, GLA.
• DHASCO defined herein as docosahexaneoic acid- containing single cell oil
• DHA is a C22:6 omega-3 long chain PUFA.
• EPASCO defined herein as eicosapentaneoic acid- containing single cell oil
• Nitzschia alba as disclosed in above- referenced U.S. application 07/496,572.
• EPA is a C20:5 omega-3 long chain PUFA.
• ARASCO defined herein as arachidonic acid- containing single cell oil, can be obtained from species such as Pythi m Insldiosum, or Mortlerella alpina, as described in U.S. application 07/645,454.
• ARA is a C20:4 omega-6 long chain PUFA.
• Another aspect of the invention discloses a process for supplementing or altering the composition of commercially available infant formula so as to provide them with a PUFA composition more nearly like that typically contained in human breast milk.
• "Typical" as used herein refers to the average amounts of PUFAs measured.
• a nursing mother choosing to switch to formula can have her breast milk analyzed for PUFA content.
• an additive for a commercially available formula which will supply comparable amounts of PUFAs can be specifically designed.
• Long chain PUFA-containing microbial oils from at least two microorganisms can be obtained and blended together to provide the desired composition.
• the blend then can be added to an infant formula.
• an amount of the blend effective to provide an amount of the desired PUFAs substantially similar to that found in human breast milk will be provided.
• human breast milk contains from about 0.5 to 0.6% of its fatty acid content as ARA, from about 0.15 to about 0.36% of its fatty acid content as DHA and from about 0.03 to about 0.13% of its fatty acid content as EPA.
• ARA fatty acid content
• DHA fatty acid content
• EPA fatty acid content
• a preferred ratio of ARA:DHA:EPA is from about 5:1:1 to about 20:10:1 respectively. Amounts of oils providing approximately these ratios of PUFAs can be determined without undue experimentation by those of skill in the art.
• the microbial oils include .ARASCO and DHASCO and EPASCO or any combination thereof. It is also preferred to use oil from microbes of the genera Mortierella, Pythium, Crypthecod ⁇ nium , and Nltzschia or any combination thereof. Particularly preferred species from these genera are M. alpina , P. in ⁇ idio ⁇ um, C. cohnli and N. alba . This preferred embodiment would provide an acceptable alternative for vegetarians, including breast-feeding or pregnant vegetarian women.
• fish oil can be blended, or mixed, with any combination of, or individual, microbial oil to produce a composition which, when subsequently added to infant formula will alter the PUFA content thereof in a desirable manner. Such a composition would not be suitable for a strict vegetarian intake.
• a preferred fish oil is specially processed Menhaden Oil (produced by Zapata Hayne, Inc.) which typically contains about 9% DHA. Of course, other fish oils also can be used.
• DHASCO is to be blended with ARASCO, and no other PUFA-containing oils are to be utilized, it is desirable to blend sufficient amounts of the oils to provide from about 1 to about 5 parts DHA with from about 2 to about 12 parts .ARA.
• a most preferred ratio of DHA to ARA is 1:3 respectively.
• Menhaden fish oil typically contains about 9% by weight DHA.
• ARASCO typically contains about 20 - 40% by weight ARA.
• DHASCO typically contains about 25 - 40% by weight DHA. It has been found that a blend of 1 part Menhaden oil containing about 9% by weight DHA with 10 parts ARASCO containing about 33% by weight ARA and 3 parts DHASCO containing about 35% by weight DHA, when added to infant formula, causes the infant formula to closely approximate the .ARA and DHA content of human breast milk. Other ratios can be readily calculated.
• a process for making a supplement for infant formula or baby food which entails blending a DHA- containing oil with a GLA-containing oil.
• the source of the GLA can be a vegetable oil, such as primrose, black currant or borage oil, or a microbial oil such as the oil from Mucor javonicus or Mortlerella Isabelllna , for example.
• Table 1 sets forth the GLA composition of such oils.
• compositions including a blend of any combination of the above-described microbial oils with or without either, or both, fish oil and vegetable oil is another aspect of the present invention. While the composition includes any ratios of the oils, the ratios previously described are preferred.
• the composition serves as a nutritional supplement.
• such supplements are encapsulated, such as in gelatin capsules.
• Such capsules provide an easy form of administration to persons having a need for supplementation, such as pregnant or nursing women.
• parenteral administration is a viable option and in one embodiment the composition comprises the fat component of a total parenteral nutritional formula.
• Such formulas are known and commercially available.
• the composition of the present invention is particularly useful as a dietary supplement for pregnant or nursing women. Vegetarian women, in particular, may require increased amounts of DHA and ARA, yet have been precluded from obtaining such in the past because the only available sources were animal.
• the aeration rate was increased to 3 SCFM.
• an additional 2 liters of 50% glucose syrup (1 kg glucose) were added.
• the fermentor was harvested, resulting in a yield of about 2.2 kg wet weight (approximately 15 g dry weight) per liter.
• Harvested biomass was squeezed to a high solids cake (50% solids) on a suction filter before freeze drying.
• the dried biomass was ground with a mortar and pestle and extracted with 1 liter of hexane per 200 grams of dry biomass at room temperature under continuous stirring for 2 hours. The mixture then was filtered and the filtrate evaporated to yield about 5-6 grams of crude oil per 100 grams of dry biomass.
• the biomass then was reextracted with 1 liter of ethanol per 20 grams of dry biomass for 1 hour at room temperature, filtered, and the solvent evaporated yielding an additional 22 grams of crude oil per 100 grams of dry biomass.
• the second fraction was predominantly phospholipids whereas the first fraction contained a mixture of phospholipids and triglycerides.
• the combined fractions produced an oil containing about 30-35% arachidonic acid and no detectable EPA.
• Mortlerella alplna (ATCC #42430) was grown in a 2 liter shake flask containing 1 liter of tap water and 20 grams of potato dextrose medium. The flask was under constant orbital agitation and was maintained at 25°C for seven days. After harvesting by centrifugation, the biomass was freeze dried yielding about 8 grams of lipid-rich mycelia. The mycelia was extracted using hexane as in example #1 and about 2.4g of crude oil resulted. This oil contains about 23% arachidonic acid.
• Example 3 Into a 30-liter working volume STF was loaded a medium of one quarter strength artificial seawater. Six liters of 10 were combined with 18 liters of tap water. The fermentor containing the medium was sterilized and cooled to 28°C. Four hundred ml of concentrated YE (455g/l), 900 ml of glucose syrup (400 g/1) and one liter of inoculum from a seed fermentor containing about 2 x 10 7 C. cohnll cells/ml or a biomass of 20 g/liter (yielding a final concentration of about 10 5 cells/ml or a biomass of about 700 mg/liter), were added to the medium. The C.
• cohnll cells designated MK8840
• ATCC 40750 Agitation was set at 120 cm/sec tip speed and aeration was set at 1 WM (30 liters per minute). Additional glucose syrup (900 ml) was added after 30 hours and another 4.2 liters over the next 42 hours. Thus 6 liters of glucose syrup were added in total. Concentrated YE solution (400 ml) was added at hour 6 and another 1.2 liters were added over the next 48 hours until a total of 2.0 liters had been added. To maintain the D.O. at greater than 20%, at 24 hours the agitation tip speed was increased to 150 cm/sec and at 48 hours to 160 cm/sec.
• the tip speed was increased to 200 cm/sec and the culture was permitted to grow for an additional time sufficient to convert the final charge of glucose into cellular oil.
• the culture was then harvested by centrifugation with the cell pellet retained.
• the harvested pellet of cells was frozen and dried (lyophilized) to about a 4% moisture content.
• Hexane (2.8 liters) was added to the dried biomass and stirred in a glass kettle for 1.5 hours at 50°C.
• a rotary evaporator was used to remove the hexane, producing about 175 g of crude DHA- containing oil.
• STF stirred tank fermentor
• Table A exclusive of the vitamins, glucose and silicate.
• the fermentor is equipped with a Rushton- type turbine agitator.
• the STF and the medium are sterilized.
• the vitamins are added, followed by the addition of sufficient amounts of 40% glucose syrup to provide a glucose concentration of about 80 g/1.
• Concentrated sodium metasilicate pentahydrate (100 g/1) is then added to provide a total silicate concentration of about 200 mg/1.
• the inoculating amount of culture of N is then added to provide a total silicate concentration of about 200 mg/1.
• alba cells obtained from the .American Type Culture Collection as ATCC 40775 is added in an amount approximately equal to 5% of the total volume of the fermentor, e.g. 1.5 liters/30 liters. Agitation is commenced with the tip speed set to 85-90 cm/sec and air sparging at 1 WM started. Over about 16 hours an additional charge of concentrated metasilicate (0.53 liters) is added and the agitation speed increased to 126 cm/sec. Over about the next 24 hours, more concentrated silicate (0.83 liters) is added. Agitation speed again is increased to about 180-185 cm/sec. Over about the next 3 hours an additional 0.15 liters of concentrated metasilicate is added.
• the total amount of metasilicate added is about 156 grams or about 1.6 liters of concentrated solution.
• additional glucose about 5 liters
• additional glucose about 4.8 Kg or about 12 liters of 40% glucose syrup.
• the culture is permitted to grow for an additional 16 hours, maintaining the agitation speed and aeration rate.
• the fermentor is harvested using a Sharpies continuous flow centrifuge producing a biomass density of approximately 45-48 grams dry weight per liter.
• the resulting pellet about 20-38% solids, is removed and frozen to about -20°C.
• a vacuum tray drier is used to remove water from the pellet.
• the single cell oil pellet then is extracted with hexane.
• the hexane subsequently is removed by distillation leaving the extracted single cell oil.
• the first mixture represents a totally vegetarian source of an arachidonic and docosahexaenoic acid supplement. This supplement would be considered acceptable to persons restricted to a vegetarian diet.
• Sanders et al. (Amer. J. Clin. Nutr. 31:805; 1978) have reported that the DHA levels in the breast milk of vegetarian mothers are depressed. Enteral supplementation of a blend of DHA single cell oil and ARA single cell oil will elevate the serum and, hence, breast milk levels of DHA to that of omnivorous mothers.
• This blend is prepared by mixing one part DHASCO containing about 35% DHA (obtained from Crypthecodlnxum cohnll as described in Example 3) with three parts ARASCO containing about 33% ARA (obtained from Pythlum Insidiosum as described in Example 1).
• the resulting mixture, or blend has the fatty acid composition shown in Table 2.
• the blend is mixed in a ratio of one part blend to forty parts of the oils regularly in infant formula, typically about 2.8 - 3.0 grams per 100 ml of formula. At a normal fat content of 30g fat per liter of Similac ® infant formula, this corresponds to the addition of 750 mg per liter of prepared formula.
• This supplement provides ARA and DHA levels equivalent to human breast milk.
• This mixture represents a totally vegetarian source of long chain PUFAs and would be considered acceptable to persons restricted to a vegetarian diet.
• This blend is prepared by mixing three parts DHASCO containing about 35% DHA (obtained from Crypthecodlnl um cohnll as described in Example 3) with ten parts ARASCO containing about 33% ARA (obtained from Pythlum Insidiosum as described in Example 1) and five parts
• EPASO containing about 5% EPA obtained from N. alba as described in Example 4
• the resulting mixture, or blend has the fatty acid composition shown in Table 3.
• the blend is mixed in a ratio of one part blend to thirty parts of the oils regularly in infant formula. At a normal fat content of 30g fat per liter of Similac® infant formula, this would correspond to the addition of one gram per liter of prepared formula.
• This supplement provides ARA, DHA and EPA levels equivalent to human breast milk.
• This mixture is a blend of ARASCO with fish oils.
• Oil mixture #3 is prepared by adding one part specially processed Menhaden Oil (Zapata Hayne Inc. ) containing about 9% DHA to one part of ARASCO, obtained from Pythlum Insidiosum as described previously containing about 33% .ARA.
• the resultant fatty acid composition is shown in Table 4.
• This blend is mixed in a ratio of one part blend to thirty parts of the oils regularly in infant formula. At a normal fat content of 30 g fat per liter of infant formula, this corresponds to the addition of 1 gram per liter of prepared formula.
• This supplement provides ARA and DHA levels equivalent to human breast milk, but the EPA levels are about eight ⁇ fold higher than those in breast milk.
• Oil mixture #4 was developed to utilize GLA in place of arachidonic acid.
• This blend was prepared by mixing one part specially prepared Menhaden oil containing about 9% DHA (Zapata Hayne Inc.) with four parts black currant seed oil containing about 18% GLA and one part DHASCO containing about 35% DHA.
• the resultant fatty acid composition is shown in Table 5.
• This blend is mixed in a ratio of one part blend to forty parts of the oils regularly in infant formula. At a normal fat content of 30g fat per liter, this would correspond to the addition of 750 mg per liter of prepared formula.
• This supplement provides EPA and DHA levels equivalent to human breast milk.
• the ARA levels are about one tenth the level in human breast milk.
• the GLA levels are twenty to fifty times higher than the GLA levels in breast milk which typically are minute.
• Oil mixture #5 was developed to best approximate the composition of DHA, ARA and EPA of human breast milk.
• This oil blend was prepared by mixing one part specially prepared Menhaden oil containing about 9% DHA (Zapata Hayne Inc.) with ten parts of ARASCO containing about 33% ARA and three parts DHASCO containing about 35% DHA.
• the resultant fatty acid composition is shown in Table 6.
• This blend is mixed in a ratio of one part blend to forty parts of the oils regularly in infant formula. At a normal fat content of 30g fat per liter of infant formula, this corresponds to the addition of 750 mg per liter of prepared formula.
• This supplement provides EPA, DHA and ARA levels substantially equivalent to those levels in human breast milk.
• Table 6 Composition of a blend of SPMO, .ARA oil and DHA oi weight.
• This mixture represents a totally vegetarian source of arachidonic and docosahexaenoic acid. This supplement would be considered acceptable to persons restricted to a vegetarian diet.
• Sanders et al. (American J. Clin . Nutr. 32:805; 1978) have reported that the DHA levels in the breast milk of vegetarian mothers are depressed. Enteral supplementation of the blend will elevate the serum and hence breast milk levels of DHA to that of omnivorous mothers.
• This blend is prepared by mixing one part DHA oil (obtained from Crypthecodlnlum cohnll as described in Example 3) with five parts ARA oil (obtained from Mortlerella alplna as described in Example 2). The resulting mixture has the fatty acid composition shown in Table 7.
• This blend is mixed in a ratio of one part to thirty-five parts of the oils regularly in infant formula. At a normal fat content of 35 g fat per liter, this would correspond to the addition of 1 g per liter of prepared formula.
• This supplement provides ARA and DHA levels equivalent to human breast milk.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Pharmacology & Pharmacy (AREA)
• Food Science & Technology (AREA)
• Medicinal Chemistry (AREA)
• Polymers & Plastics (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Nutrition Science (AREA)
• Mycology (AREA)
• Epidemiology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Emergency Medicine (AREA)
• Pediatric Medicine (AREA)
• Hematology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Obesity (AREA)
• Diabetes (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Dairy Products (AREA)
• Fats And Perfumes (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Medicines Containing Plant Substances (AREA)
• Seasonings (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Edible Oils And Fats (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Processing Of Solid Wastes (AREA)
• Fodder In General (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Publications (1)

Family

ID=24589106

Family Applications (1)

Country Status (20)

Cited By (41)

Families Citing this family (376)

Citations (4)

Family Cites Families (65)

• 1992
  • 1992-01-22 SG SG1996008986A patent/SG49307A1/en unknown
  • 1992-01-22 ES ES92904388T patent/ES2157898T3/es not_active Expired - Lifetime
  • 1992-01-22 DK DK92904388T patent/DK0568606T3/da active
  • 1992-01-22 BR BR9205526A patent/BR9205526A/pt not_active Application Discontinuation
  • 1992-01-22 ZA ZA92452A patent/ZA92452B/xx unknown
  • 1992-01-22 IL IL10073392A patent/IL100733A/en not_active IP Right Cessation
  • 1992-01-22 JP JP4504606A patent/JP2731035B2/ja not_active Ceased
  • 1992-01-22 WO PCT/US1992/000522 patent/WO1992012711A1/en not_active Ceased
  • 1992-01-22 NZ NZ241359A patent/NZ241359A/en not_active IP Right Cessation
  • 1992-01-22 AT AT92904388T patent/ATE200619T1/de not_active IP Right Cessation
  • 1992-01-22 EP EP07002670A patent/EP1787532A3/en not_active Withdrawn
  • 1992-01-22 DE DE0568606T patent/DE568606T1/de active Pending
  • 1992-01-22 AU AU12392/92A patent/AU661297B2/en not_active Expired
  • 1992-01-22 EP EP07075341A patent/EP1832181A3/en not_active Withdrawn
  • 1992-01-22 KR KR1019930702205A patent/KR100321543B1/ko not_active Expired - Lifetime
  • 1992-01-22 DE DE69231793T patent/DE69231793T2/de not_active Revoked
  • 1992-01-22 EP EP92904388A patent/EP0568606B1/en not_active Revoked
  • 1992-01-22 IL IL114253A patent/IL114253A/xx not_active IP Right Cessation
  • 1992-01-22 CA CA002101274A patent/CA2101274C/en not_active Expired - Lifetime
  • 1992-01-22 EP EP01200067A patent/EP1092352A3/en not_active Withdrawn
  • 1992-01-22 RU RU9293052410A patent/RU2093996C1/ru active
  • 1992-01-22 EP EP08005794A patent/EP1961312A3/en not_active Withdrawn
  • 1992-01-24 MX MX9200320A patent/MX183638B/es unknown
  • 1992-09-14 US US07/944,739 patent/US5374657A/en not_active Expired - Lifetime
• 1993
  • 1993-07-23 OA OA60396A patent/OA10348A/en unknown
• 1994
  • 1994-12-19 US US08/358,474 patent/US5550156A/en not_active Expired - Lifetime
• 2000
  • 2000-03-30 KR KR20007003480A patent/KR100292103B1/ko not_active Ceased
• 2001
  • 2001-02-22 KR KR20017002283A patent/KR100313987B1/ko not_active Expired - Lifetime
  • 2001-06-27 GR GR20010400993T patent/GR3036139T3/el not_active IP Right Cessation

Patent Citations (4)

Non-Patent Citations (1)

Also Published As